Adverse Prognostic Impact of Postoperative Complications After Gastrectomy for Patients With Stage II/III Gastric Cancer: Analysis of Prospectively Collected Real-World Data

Jeong Ho Song1,2, Sejin Lee1,2, Seohee Choi1,2, Minah Cho1,2, In Gyu Kwon1,2, Yoo Min Kim1,2, Taeil Son1,2, Hyoung-Il Kim1,2, Minkyu Jung2,3 and Woo Jin Hyung1,2*

1 Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea, 2 Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea, 3 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Background: The impact of postoperative complications on the prognosis of gastric cancer remains controversial. This study aimed to evaluate the relationship between postoperative complications and long-term survival in patients undergoing gastrectomy for stage II/III gastric cancer.

Methods: Some 939 patients underwent curative gastrectomy for stage II/III gastric cancer were identified from real-world data prospectively collected between 2013 and 2015. We divided patients according to the presence of serious complications, specifically, Clavien-Dindo grade III or higher complications or those causing a hospital stay of 15 days or longer.

Results: Serious complications occurred in 125 (13.3%) patients. Patients without serious complications (64.3%) completed adjuvant chemotherapy significantly more than patients with serious complications (37.6%; p<0.001). The 5-year overall survival (OS) rate was 58.1% and recurrence-free survival (RFS) rate was 58.1% in patients with serious complications, which were significantly worse than those of patients without serious complications (73.4% and 74.7%, respectively; p<0.001 for both). In stage II, once patients completed adjuvant chemotherapy adequately, the OS and RFS of patients with serious complications did not differ from those without serious complications. However, in stage III, the patients with serious complications showed a worse OS even after completion of adequate adjuvant chemotherapy.

Conclusion: Serious complications after gastrectomy had a negative impact on the prognosis of stage II/III gastric cancer patients. Serious complications worsen the survival in association with inadequate adjuvant chemotherapy. Efforts to reduce serious complications, as well as support adequate chemotherapy through proper
 management of serious complications, would improve the prognosis of stage II/III gastric cancer patients.

**Keywords: gastric cancer, complication, chemotherapy, prognosis, real-world data (RWD)**

**INTRODUCTION**

Over a million new gastric cancer are diagnosed worldwide, making it the fifth most common cancer and the third leading cause of cancer death (1). Radical gastrectomy provides the only definitive chance to cure gastric cancer (2, 3); however, patients who undergo gastrectomy frequently experience postoperative complications. The complication rates following gastrectomy for gastric cancer is reported to be approximately 10–60% (4, 5), with 1.3–12.5% of major complications (6, 7), despite recent advances in surgical techniques and perioperative patient care.

Complications after cancer surgery have detrimental effects on the prognosis of cancer patients, which has been shown in colorectal cancer (8), head and neck cancer (9), and esophageal cancer (10). Several studies have evaluated the impact of postoperative complications on the long-term outcome of gastric cancer patients (5, 6, 11–13). However, the prognostic impact of complications after gastrectomy on gastric cancer patients remains controversial. These conflicting results are derived from the potential under-reporting of complications and their management in retrospective studies, as well as the selection bias of enrolling relatively physically fit patients in prospective studies. Data from a real-world setting may overcome these drawbacks and clarify the prognostic impact of complications after gastrectomy.

We hypothesized that the effect of complications after gastrectomy on the prognosis of gastric cancer patients could be exactly evaluated with prospectively collected real-world data. This study aimed to investigate the relationship between postoperative complications and long-term survival in a large cohort of patients undergoing gastrectomy for gastric cancer using prospectively collected real-world data.

**MATERIALS AND METHODS**

**Patients**

A prospectively collected gastric cancer database consisting of 3363 patients who underwent gastrectomy from January 2013 to December 2015 was reviewed retrospectively. A total of 1009 patients with pathologic stage II/III gastric cancer who underwent curative gastrectomy was identified from the database. Patients who met any of the following criteria were excluded from the analysis: completion total gastrectomy, gastrectomy combined with other cancer surgery, history of preoperative chemotherapy or radiotherapy, mortality or recurrence within 3 months of the operation, and lost to follow-up. No patient died of complications three months after gastrectomy. This study was approved by the Institutional Review Board of Severance Hospital, Yonsei University Health System (Protocol 4-2020-0303).

**Surgery**

Seven surgeons performed gastrectomy for gastric cancer. Three of them performed only open surgery, whereas the other four surgeons performed minimally invasive surgery (MIS), including laparoscopic and robotic surgery, as well as open surgery. MIS was usually performed for patients with serosa-negative advanced gastric cancer with or without limited involvement of perigastric lymph nodes. In contrast, patients with serosa-positive advanced gastric cancer or extensive involvement of perigastric lymph nodes were generally considered for open gastrectomy. The gastric resection extent (total, distal subtotal, or proximal gastrectomy) was determined based on tumor location. D1+ lymphadenectomy was performed for early-stage gastric cancer and D2 lymphadenectomy was performed for advanced gastric cancer. The reconstruction method used for distal subtotal gastrectomy was gastroduodenostomy, gastrojejunostomy, or Roux-en Y gastrojejunostomy. The reconstruction method used for total gastrectomy was Roux-en Y esophagejejunostomy and that of proximal gastrectomy was double tract reconstruction (14). Tumor stage was defined according to the 8th edition of American Joint Committee on Cancer staging system (15).

**Perioperative Management**

At our institution, we established a “standard clinical pathway” for patients undergoing gastrectomy. We injected prophylactic antibiotics 15 minutes before surgery without administering routine postoperative antibiotics. We only used postoperative antibiotics in cases where gross bowel content contamination occurred during surgery or when symptoms and signs of inflammation, such as fever and leukocytosis, persisted for 3 days or more after surgery. We indwelled a urinary catheter in the operating room after anesthesia and removed it on postoperative day (POD) 1. Nasogastric tube was not inserted routinely, but rather only for patients with pyloric obstruction. Postoperative pain was primarily managed by patient-controlled anesthesia, and non-steroidal anti-inflammatory drugs were used for additional pain control. Intravenous antiemetics were injected every 12 hours only on the day of operation. Mucolytics were administered every 8 hours until POD 2 to support pulmonary toileting. Patients started drinking water on POD 2, having liquid diet on POD 3, and eating a soft diet on POD 4. On POD 5, patients were recommended to be discharged if ready.

Details of data collection and classification of postoperative complications are described in the Supplementary Methods.
Adjuvant Chemotherapy
After surgery, patients with pathologic stage II/III gastric cancer were recommended to receive 5-FU-based adjuvant chemotherapy within 4–8 weeks after surgery. Old age itself was not a contraindication to adjuvant chemotherapy, but chemotherapy was not performed when the patient refused it or the patient’s performance status was poor. A majority of adjuvant chemotherapy regimens were TS-1 monotherapy or XELOX (capecitabine plus oxaliplatin), which were used to treat patients with stage II or stage III disease, respectively. TS-1 (80–120 mg per day) was administered for 4 weeks, followed by 2 weeks of rest. This 6-week regimen was repeated for eight cycles (16). The XELOX regimen involved 3-week cycles of oral capecitabine (1,000 mg/m² twice daily on days 1–14 of each cycle) plus intravenous oxaliplatin (130 mg/m² on day 1 of each cycle). The XELOX treatment regimen was administered for eight cycles (17).

Follow Up
We followed up with all patients every 3 months for 1 year after surgery, and then every 6 months thereafter. They underwent abdomino-pelvic computed tomography (CT) scans every 6 months for 5 years after surgery. We performed an upper endoscopy every year. Recurrence was confirmed either by radiologic studies, such as CT, positron emission tomography, whole-body bone scan, or endoscopic examination with biopsy, or by surgery.

Statistical Analysis
The serious complication (SC) group consisted of patients with Clavien-Dindo grade III or higher complications or patients with any complications causing a hospital stay of 15 days or longer. Patients without complications or who stayed in the hospital for less than 15 days with Clavien-Dindo grade I/II complications were defined as the non-serious complication (non-SC) group. We defined the adequate adjuvant chemotherapy group as patients who completed chemotherapy without omission or delayed initiation, while the inadequate adjuvant chemotherapy group as patients who omitted, delayed in initiation, or not completed the scheduled chemotherapy. Delayed initiation in adjuvant chemotherapy was defined as starting at 8 weeks after surgery (18), and incompletion of adjuvant chemotherapy was defined as discontinued treatment during the scheduled chemotherapy cycles.

Chi-square or Fisher’s exact tests for categorical variables and the Mann-Whitney test for continuous variables were used. The Kaplan-Meier method was used to calculate the overall and recurrence-free survival, whereas differences between survival curves were assessed using the log-rank test. The hazard ratio (HR) and two-sided 95% confidence intervals (CI) were estimated using a Cox proportional hazards model. A P-value less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software for Windows (version 25.0; IBM Corp., Armonk, New York, USA).

RESULTS

Patient Characteristics
A retrospective review of prospective data revealed 1009 patients who underwent curative gastrectomy for stage II/III gastric cancer. After 70 patients were excluded from the analyses (completion total gastrectomy [n=28]; combined other cancer surgery [n=17]; history for preoperative chemotherapy or radiotherapy [n=4]; mortality or recurrence within postoperative 3 months [n=17]; and follow-up loss [n=4]), data from 939 patients were included in this study.

Patient clinicopathologic characteristics are summarized in Table 1. The median age was 60 years (interquartile range (IQR), 52–70) and most patients were male (n=591; 62.9%). The median BMI was 22.9 (IQR 20.8–25.0) with 229 patients (24.4%) exhibiting a BMI of 25 or higher. The 68.5% of all patients (n=643) underwent open gastrectomy. The majority of patients underwent subtotal gastrectomy (n=641; 68.3%). This study consisted of 463 (49.3%) and 476 (50.7%) patients with pathologic stage II and stage III disease, respectively. Complications occurred in 741 out of 939 patients (78.9%), of which the number of patients with Clavien-Dindo grade I/II or grade III and higher was 655 (69.8%) or 86 (9.2%), respectively. (Additional details related to postoperative complications are in Supplementary Table S2). The non-SC group consisted of 198 patients without complications and 616 patients with complications less than 15 days of hospital stay. The SC group consisted of 86 patients with Clavien-Dindo grade III or higher and 39 patients with any complications causing a hospital stay of 15 days or longer. The SC group was more likely to be characterized by old age, male, and higher American Society of Anesthesiology (ASA) scores than the non-SC group (P=0.001, P=0.04, and P=0.021, respectively). The occurrence of serious complications was associated with tumors located in the upper body of the stomach or advanced tumor, which required total gastrectomy and open surgery rather than MIS (Table 1).

Compared with the non-SC group, patients who stayed in the hospital for 15 days or longer with Clavien-Dindo grade I/II complications were significantly associated with old age, high ASA score, open surgery, and combined operation (P=0.040, P=0.025, P<0.001, and P=0.011, respectively; Supplementary Table S3). The clinicopathologic characteristics of patients with Clavien-Dindo grade I/II complications causing a hospital stay of 15 days or longer were similar to those with Clavien-Dindo grade III or higher complications, except for histology (Supplementary Table S4). The median hospital stays of patients with Clavien-Dindo grade I/II complications causing a hospital stay of 15 days was 16 days (IQR 15–22), which was similar to that of patients with Clavien-Dindo grade III or higher complications (median 15; IQR 10–22). The median stay for the non-SC group was 7 days (IQR 6–8).

Relationship Between Postoperative Complication and Adjuvant Chemotherapy
Overall, 750 of 939 (79.9%) patients were treated with adjuvant chemotherapy. The SC group was associated with a higher rate of
TABLE 1 | Comparison of clinicopathologic characteristics according to serious complications.

| Overall (n=939) | Non-SC group (n=814) | SC group (n=125) | P-value |
|-----------------|----------------------|------------------|---------|
| Age, median (IQR), years | 60 (52–70) | 60 (52–60) | 66 (54–74) | 0.001 |
| Sex | | | | 0.04 |
| Female | 348 (37.1%) | 312 (38.3%) | 36 (28.8%) | |
| Male | 591 (62.9%) | 502 (61.7%) | 89 (71.2%) | |
| BMI, median (IQR), kg/m² | 22.9 (20.8–25.0) | 22.8 (20.8–25.0) | 23.3 (20.6–25.4) | 0.477 |
| ASA score | 8 (0.9%) | 6 (0.7%) | 2 (1.6%) | |
| Operation method | | | | <0.001 |
| Open | 643 (68.5%) | 534 (65.6%) | 109 (87.2%) | |
| Laparoscopy | 189 (20.1%) | 180 (22.1%) | 9 (7.2%) | |
| Robot | 107 (11.4%) | 100 (12.3%) | 7 (5.6%) | |
| Surgical procedure | | | | 0.001 |
| STG | 641 (68.3%) | 573 (70.4%) | 68 (54.4%) | |
| TG | 294 (31.3%) | 238 (29.2%) | 56 (44.8%) | |
| PG | 4 (0.4%) | 3 (0.4%) | 1 (0.8%) | |
| Lymph node dissection | | | | 0.129 |
| N <2 | 105 (11.2%) | 96 (11.8%) | 9 (7.2%) | |
| N ≥2 | 834 (88.8%) | 718 (88.2%) | 116 (92.8%) | |
| Combined operation | | | | <0.001 |
| No | 788 (83.9%) | 703 (86.4%) | 85 (68.0%) | |
| Yes | 151 (16.1%) | 111 (13.6%) | 40 (32.0%) | |
| Histology | | | | 0.085 |
| Differenentiated | 305 (32.5%) | 256 (31.4%) | 49 (39.2%) | |
| Undifferentiated | 634 (67.5%) | 558 (68.6%) | 76 (60.8%) | |
| Tumor depth | | | | 0.043 |
| T1 | 56 (6.0%) | 52 (6.4%) | 4 (3.2%) | |
| T2 | 130 (13.8%) | 116 (14.3%) | 14 (11.2%) | |
| T3 | 341 (36.3%) | 294 (36.1%) | 47 (37.6%) | |
| T4a | 399 (42.5%) | 344 (42.3%) | 55 (44.0%) | |
| T4b | 13 (1.4%) | 8 (1.0%) | 5 (4.0%) | |
| Lymph node metastasis | | | | 0.682 |
| N0 | 226 (24.1%) | 201 (24.7%) | 25 (20.0%) | |
| N1 | 187 (19.9%) | 159 (19.5%) | 28 (22.4%) | |
| N2 | 241 (25.7%) | 208 (25.6%) | 33 (26.4%) | |
| N3 | 285 (30.4%) | 246 (30.2%) | 39 (31.2%) | |
| Pathologic stage | | | | 0.097 |
| I | 463 (49.3%) | 410 (50.4%) | 53 (49.6%) | |
| II | 476 (50.7%) | 404 (42.4%) | 72 (67.6%) | |
| Complication | | | | 0.001 |
| No | 198 (21.1%) | 198 (24.3%) | 0 | |
| Yes | 741 (78.9%) | 616 (75.7%) | 125 (100%) | |

SC, serious complications; IQR, interquartile range; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); ASA, American Society of Anesthesiology; STG, subtotal gastrectomy; TG, total gastrectomy; PG, proximal gastrectomy.

*aPathologic stages were defined in accordance with the 8th edition of American Joint Committee on Cancer staging system.

omission (n=41, 32.8%) than the non-SC group (n=148, 18.2%; P<0.001). The SC group also exhibited more instances of delayed initiation, incompleteness, and inadequacy of adjuvant chemotherapy (n=8, 9.5%; n=32, 38.1%; n=78, 62.4%) than the non-SC group (n=14, 2.1%; P=0.002; n=135, 20.3%, P<0.001; n=291, 35.7%, P<0.001, respectively) (Table 2). Similar findings were observed in stages II and III (Supplementary Table S5, S6), with only marginal differences seen in the number of patients who did not complete their chemotherapy.

The rate of omission and inadequacy of adjuvant chemotherapy were significantly higher in Clavien-Dindo grade I/II patients who stayed 15 days or longer in the SC group compared to the non-SC group (Supplementary Table S7). However, the rate of omission, delayed initiation, incompleteness and inadequacy of adjuvant chemotherapy were similar between the Clavien-Dindo grade I/II patients who stayed 15 days or longer and those with Clavien-Dindo grade III or higher complications (Supplementary Table S8).

Survival Outcomes

The median follow-up duration after surgery was 52 months (range: 7–71 months) until the cutoff date of December 31, 2018. During the follow-up period, 245 patients (26.1%) died, of which 52 (41.6%) were from the SC group and 193 (23.7%) were from the non-SC group. The HR for death in the SC group, as compared with that in the non-SC group, was 1.92 (95% CI, 1.4–2.6; P<0.001). The 5-year overall survival rate of the SC group was 58.1% (95% CI, 49.2–68.6) and that of the non-SC group was 71.3% (95% CI, 70.0–76.9; log-rank P<0.001) (Figure 1).

The number of patients that experienced a recurrence was 240 (25.6%), of which 58 (46.4%) were from the SC group and 182 (22.4%) were from the non-SC group. The HR for recurrence in the SC group, as compared to the non-SC group, was 1.75 (95% confidence interval: 1.0–2.9).

TABLE 2 | Relationship between postoperative complications and adjuvant chemotherapy.

| Adjuvant chemotherapy | Overall (n=939) | Non-SC group (n=814) | SC group (n=125) | P-value |
|-----------------------|-----------------|----------------------|------------------|---------|
| Omission | 939 | 750 (79.9%) | 666 (81.8%) | 84 (67.2%) | <0.001 |
| Time to AC | 750 | 189 (20.1%) | 148 (18.2%) | 41 (32.8%) | 0.002 |
| Scheduled cycles of AC | 750 | 622 (97.1%) | 562 (97.9%) | 76 (90.5%) | <0.001 |
| Adjuvantic | 939 | 570 (60.7%) | 523 (64.3%) | 47 (37.6%) | <0.001 |
| Inadequate | 369 (39.3%) | 291 (35.7%) | 78 (62.4%) | |

SC, serious complications; AC, adjuvant chemotherapy.

*aAdequate AC was defined when AC was completed without omission or delayed initiation.

*bInadequate AC was defined when AC was omitted, delayed initiation, or not completed the scheduled chemotherapy cycles.
CI, 1.3–2.4; P=0.001). The 5-year recurrence-free survival rate in SC patients was 58.1% (95% CI, 49.0–69.0) and that in non-SC patients was 74.7% (95% CI, 71.5–77.9; log-rank P<0.001) (Figure 1). When we stratified the patients according to pathologic stages, the SC group exhibited worse overall and recurrence-free survival rates than the non-SC group for patients with stages II and III (Supplementary Figure S1).

Survival outcomes were also compared after dividing the patients into three groups, namely non-SC patients who received adequate chemotherapy (n=523), SC patients who received adequate chemotherapy (n=47), and SC patients whose chemotherapy was inadequate (n=78). Patients who received inadequate chemotherapy in the SC group showed significantly worse overall and recurrence-free survival than non-SC patients who received adequate chemotherapy (log-rank P<0.001) (Figure 2). In stage II, SC patients who received adequate chemotherapy had similar overall and recurrence-free survival outcomes to those under adequate chemotherapy in the non-SC group (log-rank P=0.495 and P=0.936, respectively). On the contrary, in stage III, the overall and recurrence-free survival of SC patients under adequate chemotherapy were similar to those who did not receive adequate chemotherapy in the SC group (log-rank P=0.426 and P=0.551, respectively). Non-SC patients under adequate chemotherapy had significantly higher overall survival than SC patients who received adequate chemotherapy (log-rank P=0.013) even though the recurrence-free survival did not differ statistically (log-rank P=0.115) (Supplementary Figure S2).

Patients with Clavien-Dindo grade I/II complications causing a hospital stay of 15 days or longer exhibited worse overall and recurrence-free survival than those under adequate chemotherapy in the non-SC group (log-rank P=0.495 and P=0.936, respectively). On the contrary, in stage III, the overall and recurrence-free survival of SC patients under adequate chemotherapy were similar to those who did not receive adequate chemotherapy in the SC group (log-rank P=0.426 and P=0.551, respectively). Non-SC patients under adequate chemotherapy had significantly higher overall survival than SC patients who received adequate chemotherapy (log-rank P=0.013) even though the recurrence-free survival did not differ statistically (log-rank P=0.115) (Supplementary Figure S2).

Patients with Clavien-Dindo grade I/II complications causing a hospital stay of 15 days or longer exhibited worse overall and recurrence-free survival than those under adequate chemotherapy in the non-SC group (log-rank P=0.495 and P=0.936, respectively). On the contrary, in stage III, the overall and recurrence-free survival of SC patients under adequate chemotherapy were similar to those who did not receive adequate chemotherapy in the SC group (log-rank P=0.426 and P=0.551, respectively). Non-SC patients under adequate chemotherapy had significantly higher overall survival than SC patients who received adequate chemotherapy (log-rank P=0.013) even though the recurrence-free survival did not differ statistically (log-rank P=0.115) (Supplementary Figure S2).
of patients with Clavien-Dindo grade III or higher complications (Supplementary Figure S4).

Multivariable analyses of overall and recurrence-free survival identified that serious complication was not an independent risk factor among patients under adequate adjuvant chemotherapy (HR, 1.53; 95% CI, 0.9–2.6, P=0.129 for overall survival; HR, 1.32; 95% CI, 0.8–2.3, P=0.310 for recurrence-free survival; Table 3). Stratified by stages, inadequate adjuvant chemotherapy was not a risk factor among patients without serious complications (HR, 1.45; 95% CI, 0.8–2.6, P=0.215; Table 4) in the multivariable analysis of recurrence-free survival in stage II. The presence of serious complications was a risk factor for overall survival among patients under adjuvant chemotherapy in stage III (HR, 1.82; 95% CI, 1.0–3.3, P=0.043; Table 5).

Of the 240 patients with recurrence, there was no difference in recurrence pattern between the two groups (Table 6). The peritoneum was the most frequent initial site of recurrence in both groups. SC group had more frequent hematogenous metastasis (n=11, 23.9%) than the non-SC group (n=31, 16.0%), although it was not a statistically significant difference (P=0.203).

DISCUSSION

In this study, patients with serious complications demonstrated worse survival and a higher rate of disease recurrence than patients without serious complications after curative gastrectomy for stage II/III gastric cancer. A majority of patients with serious complications failed to receive adequate adjuvant therapy. Eventually, patients who experienced serious complications combined with inadequate adjuvant
Randomized controlled studies have established that adjuvant chemotherapy following gastrectomy has survival advantages compared to gastrectomy alone (16, 17). Thus, adequate delivery and completion of chemotherapy is necessary to obtain a survival benefit after curative gastrectomy for stage II/III gastric cancer. Poor survival of patients with postoperative complications after gastrectomy for stage II/III gastric cancer cannot be considered apart from adjuvant chemotherapy. As shown in this study, the SC group demonstrated a higher proportion of patients who did not receive adequate chemotherapy.

Consistent with our results, postoperative complications in gastric cancer patients prompted failure to complete multimodal chemotherapy even in a perioperative chemotherapy setting (19). Patients are relatively tolerant of perioperative chemotherapy because they receive chemotherapy under a relatively healthy condition compared to a postoperative condition. Therefore, it is difficult to determine the effect of postoperative complications on the survival outcomes of patients who have received preoperative chemotherapy because chemotherapy itself can affect postoperative complications and survival outcomes. Moreover, in the perioperative chemotherapy setting, all patients completed preoperative chemotherapy even though postoperative chemotherapy could be affected by postoperative complications. However, in the adjuvant setting, patients are affected by the effect of the complication on the whole process of chemotherapy. Thus, adverse effect of complications on

| Characteristics       | No. of patients | Overall survival | Recurrence-free survival |
|-----------------------|-----------------|------------------|--------------------------|
|                       |                 | HR   | 95% CI   | P-value | HR   | 95% CI   | P-value |
| Age                   |                 |      |         |         |      |         |         |
| ≤60 years             | 471             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| >60 years             | 468             | 1.347| 1.030–1.762| 0.096 | 1.089| 0.830–1.429| 0.691 |
| Sex                   |                 |      |         |         |      |         |         |
| Female                | 348             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| Male                  | 591             | 1.040| 0.797–1.358| 0.096 | 0.948| 0.728–1.234| 0.066 |
| ASA score             |                 |      |         |         |      |         |         |
| I or II               | 722             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| III or IV             | 217             | 1.018| 0.759–1.366| 0.096 | 0.734| 0.528–1.021| 0.044 |
| Operation method      |                 |      |         |         |      |         |         |
| MIS                   | 296             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| Open                  | 643             | 1.316| 0.952–1.819| 0.096 | 1.138| 0.818–1.582| 0.044 |
| Resection extent      |                 |      |         |         |      |         |         |
| Distal subtotal       | 641             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| Total                 | 294             | 1.066| 0.716–1.588| 0.096 | 1.300| 1.000–1.689| 0.050 |
| Proximal              | 4               | 1.322| 0.166–10.583| 0.096 | 0.734| 0.528–1.021| 0.044 |
| Lymph node dissection |                 |      |         |         |      |         |         |
| Less than D2          | 105             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| D2                    | 834             | 1.126| 0.683–1.854| 0.096 | 1.713| 0.925–3.169| 0.044 |
| Tumor size            |                 |      |         |         |      |         |         |
| ≤50 mm                | 543             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| >50 mm                | 396             | 1.682| 1.292–2.189| 0.096 | 1.849| 1.414–2.417| 0.044 |
| Tumor location        |                 |      |         |         |      |         |         |
| Lower                 | 483             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| Middle                | 248             | 1.268| 0.924–1.739| 0.096 | 0.996| 0.711–1.394| 0.044 |
| Upper/Whole           | 208             | 1.257| 0.930–1.701| 0.096 | 1.152| 0.741–1.792| 0.044 |
| Histology             |                 |      |         |         |      |         |         |
| Differentiated        | 305             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| Undifferentiated      | 634             | 1.014| 0.757–1.359| 0.096 | 0.966| 0.713–1.307| 0.044 |
| LVI                   |                 |      |         |         |      |         |         |
| (-)                   | 369             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| (+)                   | 570             | 1.093| 0.818–1.460| 0.096 | 1.129| 0.838–1.521| 0.044 |
| SC & AC               |                 |      |         |         |      |         |         |
| SC (-) & adequate AC  | 523             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| SC (+) & adequate AC  | 47              | 1.526| 0.884–2.635| 0.096 | 1.323| 0.772–2.266| 0.038 |
| SC (-) & inadequate AC| 291             | 2.293| 1.709–3.078| 0.096 | 1.599| 1.190–2.149| 0.002 |
| SC (+) & inadequate AC| 78              | 2.669| 1.807–3.942| 0.096 | 2.273| 1.524–3.388| <0.001 |
| Pathologic TNM stage  |                 |      |         |         |      |         |         |
| II                    | 463             | 1.000| 1.000–1.000| 1.000 | 1.000| 1.000–1.000| 1.000 |
| III                   | 476             | 3.197| 2.370–4.312| 0.096 | 3.137| 2.396–4.268| 0.044 |

HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious complications; AC adjuvant chemotherapy.

Adequate AC was defined when AC was completed without omission or delayed initiation.

Inadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.
chemotherapy would be greater in an adjuvant setting than in a perioperative one.

Studies analyzed the relationship among postoperative complications, chemotherapy, and survival outcomes demonstrated that survival outcomes of patients with complications who received adjuvant therapy or completed multimodal therapy were comparable to those of patients without complications, similar to this study. The prognostic impact of serious complications differed according to pathologic stage in our study. Assessing the impact of serious complications combined with the adequacy of chemotherapy on survival outcome is very complex. In this study, the presence of serious complications in stage III patients resulted in poor prognosis regardless of adequacy of chemotherapy. Since patients tolerate better with preoperative chemotherapy than postoperative adjuvant chemotherapy, preoperative chemotherapy has a higher completion rate than postoperative adjuvant chemotherapy. Preoperative chemotherapy does not increase the incidence of surgical complications (19, 20). Furthermore, the survival outcomes after preoperative chemotherapy were similar between patients who experienced postoperative complications and those who did not (21). Thus, preoperative chemotherapy may be considered for patients who are more likely to develop complications, especially when stage III is suspected by preoperative assessments. However, the adverse impact of serious complications was not profound in stage II patients. If chemotherapy was delivered adequately, even patients with serious complications in stage II demonstrated similar survival to those who did not experience serious complications. Thus, it is important to treat serious complications befittingly to administer adequate chemotherapy.

### TABLE 4 | Multivariate analyses of overall and recurrence-free survival in stage II gastric cancer patients.

| Characteristics          | No. of patients | Overall survival | Recurrence-free survival |
|--------------------------|-----------------|------------------|--------------------------|
|                          |                 | HR 95% CI        | P-value                  | HR 95% CI                        | P-value                      |
| Age                      |                 |                  |                          |                            |                              |
| ≤60 years                | 239             | 0.468            | 0.142                    | 0.373–1.152                  | 0.651                         |
| >60 years                | 224             | 1.222 0.711–2.102| 1                       | 1.152                        | 1                             |
| Sex                      |                 |                  |                          |                            |                              |
| Female                   | 164             | 1.212 0.686–2.140| 0.878                    | 0.499–1.545                  | 0.044                         |
| Male                     | 299             | 1                |                          | 1                           |                               |
| ASA score                |                 |                  |                          |                            |                              |
| I or II                  | 355             | 0.955            | 1                       | 1                           |                               |
| Ill or IV                | 108             | 1.017 0.565–1.830| 0.468                    | 0.224–0.981                  | 0.603                         |
| Operation method         |                 |                  |                          |                            |                              |
| MIS                      | 190             | 0.909            |                          | 1                           |                               |
| Open                     | 273             | 0.967 0.543–1.722| 1.168                   | 0.650–2.099                  | 0.256                         |
| Resection extent         |                 |                  |                          |                            |                              |
| Distal subtotal          | 343             | 1                |                          | 1                           |                               |
| Total                    | 117             | 1.733 1.034–2.904| 0.037                    | 1.521                        | 0.672–3.442                   | 0.314                         |
| Proximal                 | 3               | 0.974 N/A        | 0.974                    | N/A                         | N/A                           | 0.973                         |
| Lymph node dissection    |                 |                  |                          |                            |                              |
| Less than D2             | 80              | 0.534            | 1                       | 1                           |                               |
| D2                       | 383             | 1.274 0.593–2.737| 1.725                   | 0.674–4.415                  | 0.001                         |
| Tumor size               |                 |                  |                          |                            |                              |
| ≤50 mm                   | 328             | 1                |                          | 1                           |                               |
| >50 mm                   | 135             | 1.724 1.043–2.848| 2.348                   | 1.393–3.954                  | 0.044                         |
| Tumor location           |                 |                  |                          |                            |                              |
| Lower                    | 236             | 1                |                          | 1                           |                               |
| Middle                   | 136             | 0.661 0.336–1.301| 0.230                    | 0.710                        | 0.361–1.394                   | 0.319                         |
| Upper/Whole              | 91              | 0.997 0.412–2.415| 0.995                    | 1.732                        | 0.944–3.176                   | 0.076                         |
| Histology                |                 |                  |                          |                            |                              |
| Differentiated           | 163             | 0.484            |                          |                             | 0.845                         |
| Undifferentiated         | 300             | 1.223 0.697–2.146| 1.062                   | 0.581–1.944                  | 0.001                         |
| LVI                      |                 |                  |                          |                            |                              |
| (-)                      | 263             | 0.904            | 0.733                    |                             |                               |
| (+)                      | 200             | 0.967 0.562–1.665| 1.108                   | 0.616–1.991                  |                               |
| SC & AC                  |                 |                  |                          |                            |                              |
| SC (+) & adequate AC     | 241             | 1                |                          | 1                           |                               |
| SC (+) & inadequate AC   | 20              | 0.461 0.062–3.427| 0.449                    | 0.785                        | 0.184–3.347                   | 0.744                         |
| SC (+) & inadequate AC   | 169             | 1.913 1.089–3.361| 0.024                    | 1.445                        | 0.808–2.584                   | 0.215                         |
| SC (+) & inadequate AC   | 33              | 4.741 2.383–8.393| <0.001                   | 4.317                        | 2.006–9.294                   | <0.001                         |

HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious complications; AC, adjuvant chemotherapy.

* Adequate AC was defined when AC was completed without omission or delayed initiation.

* Inadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.
To consider the timely treatment of complications, we combined the length of stay and the severity of Clavien-Dindo complication grade to define serious complications. Most previous studies in gastric cancer used a modified Clavien-Dindo classification system, and grade III or higher was used to express the severity of the complication (6, 22, 23). Under this classification, many surgeons expect patients with complications to recover from conservative care without active treatment to avoid a high-grade complication rating. As a result, patients stay longer in the hospital and have poor general conditions, which is most likely adversely affects the delivery of chemotherapy and survival outcomes even without serious complications. Furthermore, patients remaining in the hospital for 15 days or longer with Clavien-Dindo grade I/II complications showed similar clinicopathologic characteristics as those with Clavien-Dindo grade III or higher complications. Similar impact on the adequacy of chemotherapy and survival outcomes was also observed. Therefore, serious complications are more suitable in determining patient group according to the severity of postoperative complications.

### TABLE 5
Multivariate analyses of overall and recurrence-free survival in stage III gastric cancer patients.

| Characteristics             | No. of patients | Overall survival | Recurrence-free survival |
|-----------------------------|-----------------|------------------|-------------------------|
|                             | HR 95% CI       | P-value          | HR 95% CI               | P-value          |
| Age                         |                |                  |                        |                  |
| ≤60 years                   | 232            | 1                | 1                       | 1.018–1.898      | 0.181           |
| >60 years                   | 244            | 1.390            | 1.018–1.898             | 1.237            | 0.906–1.688     | 0.588           |
| Sex                         |                |                  |                        |                  |
| Female                      | 184            | 0.739            | 1                       | 0.919            | 0.676–1.248     | 0.273           |
| Male                        | 292            | 0.948            | 0.692–1.299             | 0.676–1.248      | 0.541           |
| ASA score                   |                |                  |                        |                  |
| I or II                     | 367            | 0.810            | 1                       | 0.813            | 0.561–1.178     | 0.003           |
| III or IV                   | 109            | 0.958            | 0.678–1.356             | 0.919            | 0.676–1.248     | 0.541           |
| Operation method            |                |                  |                        |                  |
| MIS                         | 106            | 0.083            | 1                       | 1.333            | 0.759–1.689     | 0.146           |
| Open                        | 370            | 1.442            | 0.953–2.180             | 0.001            | 1.830–2.180     | 0.001           |
| Resection extent            |                |                  |                        |                  |
| Distal subtotal             | 298            | 0.882            | 0.555–1.402             | 0.025            | 1.200            | 0.089–1.618 | 0.233 |
| Total                       | 177            | 0.596            | 0.311–2.137             | 0.586            | 1.200            | 0.089–1.618 | 0.233 |
| Proximal                    | 1              | 2.577            | 0.311–21.371            | 0.381            | N/A              | N/A            |
| Lymph node dissection       |                |                  |                        |                  |
| Less than D2                | 25             | 0.898            | 1                       | 1.133            | 0.759–1.689     | 0.146           |
| D2                          | 451            | 1.044            | 0.541–2.014             | 1.830            | 0.810–4.134     | 0.001           |
| Tumor size                  |                |                  |                        |                  |
| ≤50 mm                      | 215            | 1                | 1                       | 1.876            | 1.381–2.549     | 0.001           |
| >50 mm                      | 261            | 1.705            | 1.252–2.322             | 1.381–2.549      | 0.001           |
| Tumor location              |                |                  |                        |                  |
| Lower                       | 247            | 1                | 1                       | 1.533            | 0.784–1.695     | 0.469           |
| Middle                      | 112            | 1.516            | 1.055–2.179             | 0.025            | 1.153            | 0.784–1.695 | 0.469 |
| Upper/Whole                 | 117            | 1.164            | 0.819–1.655             | 0.397            | 1.117            | 0.674–1.851 | 0.667 |
| Histology                   |                |                  |                        |                  |
| Differentiated              | 142            | 0.432            | 1                       | 0.117            | 0.674–1.851     | 0.667           |
| Undifferentiated            | 334            | 0.876            | 0.628–1.220             | 0.916            | 0.648–1.295     | 0.391           |
| LVI (-)                     | 106            | 0.610            | 1                       | 1.753            | 0.813–1.700     | 0.391           |
| LVI (+)                     | 370            | 1.100            | 0.763–1.586             | 1.175            | 0.813–1.700     | 0.391           |
| SC & AC                     |                |                  |                        |                  |
| SC (-) & adequate AC        | 282            | 1                | 1                       | 1.465            | 0.821–2.615     | 0.196           |
| SC (+) & adequate AC        | 27             | 1.821            | 1.020–3.250             | 0.043            | 1.465            | 0.821–2.615 | 0.196 |
| SC (-) & inadequate AC      | 122            | 2.561            | 1.825–3.594             | <0.001           | 1.622            | 1.153–2.282 | 0.005 |
| SC (+) & inadequate AC      | 45             | 2.246            | 1.401–3.599             | <0.001           | 1.791            | 1.117–2.871 | 0.016 |

HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology; MIS, minimally invasive surgery; N/A, not applicable; LVI, lymphovascular invasion; SC, Serious complications; AC, adjuvant chemotherapy.

* Adequate AC was defined when AC was completed without omission or delayed initiation.

* Inadequate AC was defined when AC was omitted, delayed in initiation, or not completed the scheduled chemotherapy cycles.

### TABLE 6
Comparison of initial recurrence site according to serious complications in patients with recurrence.

| Recurrence pattern | Overall (n=240) | Non-SC group (n=194) | SC group (n=46) | P-value |
|--------------------|-----------------|----------------------|-----------------|---------|
| Locoregional       | 23 (9.6%)       | 21 (10.8%)           | 2 (4.3%)        | 0.266   |
| Peritoneal         | 104 (43.3%)     | 85 (43.8%)           | 19 (41.3%)      | 0.757   |
| Hematogenous       | 42 (17.5%)      | 31 (16.0%)           | 11 (23.9%)      | 0.203   |
| Distant lymph node | 32 (13.0%)      | 27 (13.9%)           | 5 (10.9%)       | 0.585   |
| mixed              | 39 (16.3%)      | 30 (15.5%)           | 9 (19.6%)       | 0.496   |

SC, serious complications.

To consider the timely treatment of complications, we combined the length of stay and the severity of Clavien-Dindo complication grade to define serious complications. Most previous studies in gastric cancer used a modified Clavien-Dindo classification system, and grade III or higher was used to express the severity of the complication (6, 22, 23). Under this classification, many surgeons expect patients with complications to recover from conservative care without active treatment to avoid a high-grade complication rating. As a result, patients stay longer in the hospital and have poor general conditions, which is most likely adversely affects the delivery of chemotherapy and survival outcomes even without serious complications. Furthermore, patients remaining in the hospital for 15 days or longer with Clavien-Dindo grade I/II complications showed similar clinicopathologic characteristics as those with Clavien-Dindo grade III or higher complications. Similar impact on the adequacy of chemotherapy and survival outcomes was also observed. Therefore, serious complications are more suitable in determining patient group according to the severity of postoperative complications.
The impacts of postoperative complications on the long-term survival outcomes of cancer patients are well documented (8–10). Complication worsens the prognosis of patients with gastrointestinal cancer, including gastric cancer. The adverse effects of serious complications on prognosis in our study are consistent with the previous studies (5, 11, 19, 20). The poor prognosis of patients with serious complications was presumed since host immunosuppression and proinflammatory cytokines induce the growth of residual cancer cells (24, 25). In fact, patients who experienced anastomotic leakage, intra-abdominal infectious complications, or inflammatory complications following gastrectomy demonstrated worse survival than those without complications (5, 11, 26).

This study has several limitations. First, only a relatively small number of patients with serious complications limited to analyze the impact of the type of complications on adjuvant chemotherapy and survival outcomes. It is necessary to identify the effect of each type of complication on prognosis after gastrectomy. Second, the regimens of chemotherapy used in this study were not homogeneous, although most of patients received either TS-1 monotherapy or XELOX. Differences in chemotherapy regimen may influence the adequacy because they affect patient compliance. It is difficult to assess the precise relationship between postoperative complications and adequacy of chemotherapy with patient prognosis. Another possible limitation is the retrospective nature of this study. To exactly evaluate the prognostic impact of complications together with chemotherapy, a randomized trial would be ideal. However, a randomized clinical trial is not always feasible in complication-related research. Moreover, the patient population selected by the inclusion and exclusion criteria in a prospective study is relatively not vulnerable, resulting in fewer postoperative complications which do not reflect real clinical practice. Another pitfall of randomized clinical trials is the possibility of a selection bias in which only patients who are fit and give informed consent to participate in the study are enrolled. Therefore, patients enrolled in the randomized clinical trials of surgical procedures are relatively in good general condition. As a result, the real-world study is considered to have more generalizability compared to randomized clinical trials. Therefore, in this study, we used prospectively collected real-world data which reflected real clinical practice.

Our study confirmed that serious complications after gastrectomy had a negative impact on the prognosis of patients with stage II/III gastric cancer through a prospectively collected data analysis. Serious complications significantly worsened survival outcomes when inducing inadequacy of adjuvant chemotherapy, rather than complication themselves. Therefore, efforts should be made to reduce serious complications as well as support adequate chemotherapy in a timely manner through the proper management of serious complications, which will improve the long-term survival of patients with stage II/III gastric cancer. In addition, perioperative chemotherapy could be an alternative option for patients with a high risk of serious complications, even in Eastern countries where adjuvant chemotherapy is a standard treatment for patients with stage II/III gastric cancer.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this article are not readily available because additional study is planned with the dataset used for this manuscript. Requests to access the datasets should be directed to WH, wjhyung@yuhs.ac.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board of Severance Hospital, Yonsei University Health System (Protocol 4-2020-0303). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

JS and WH designed the study. The acquisition, analysis or interpretation of the data was conducted by JS, SL, SC, and WH. MC, YK, TS, H-IK, and WH made contribution in administrative, technical, or material support. Critical revision of the manuscript for important intellectual content was conducted by JS, SL, SC, and WH. All authors contributed to the article and approved the submitted version.

**FUNDING**

WH has stock in Hutom, received a research grant from Medtronic (4-2017-0940) and GC Pharma (4-2018-0306), and was a consultant for Ethicon and Verb Surgical. The funding sources had no role in the design and conduct of the study; collection of data, analysis and interpretation; preparation, review or approval of the manuscript; or decision to submit the manuscript for publication.

**ACKNOWLEDGMENTS**

We would like to thank the BioScience Writers for English language editing.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.611510/full#supplementary-material
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68 (6):394–424. doi: 10.3322/caac.21492

2. Brar S, Law C, McLeod R, Heyler I, Swallow C, Paxzat L, et al. Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. J Am Coll Surg (2013) 217(2):347–57.e1. doi: 10.1016/j.jamcollsurg.2013.05.033

3. Blum MA, Takashi T, Suzuki A, Ajani JA. Management of Localized Gastric Cancer. J Surg Oncol (2013) 107(3):265–70. doi: 10.1002/jso.23183

4. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical Complications After Curative D2 Gastrectomy for Gastric Cancer: The Influenza A(H1N1) Pandemic. Ann Surg Oncol (2013) 20(5):1575–80. doi: 10.1245/s10434-012-2720-9

5. Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, et al. Prognostic Significance of Complications After Curative Surgery for Gastric Cancer. Ann Surg Oncol (2014) 21(3):891–8. doi: 10.1245/s10434-013-3384-9

6. Lee KG, Lee HJ, Yang YJ, Oh SY, Bard S, Suh YS, et al. Risk Factors Associated With Complication Following Gastrectomy for Gastric Cancer: Retrospective Analysis of Prospectively Collected Data Based on the Clavien-Dindo System. J Gastrointest Surg (2014) 18(7):1269–77. doi: 10.1007/s11605-014-2525-1

7. Lee J-H, Park DJ, Kim H-H, Lee H-J, Yang H-K. Comparison of Complications After Laparoscopic-Assisted Distal Gastrectomy and Open Distal Gastrectomy for Gastric Cancer Using the Clavien–Dindo Classification. Surg Endoscopy (2012) 26(5):1287–95. doi: 10.1007/s00464-011-2027-0

8. Mrak I, Eberl T, Laske A, Jagoditsch M, Fritz J, Tschmelitsch J. Impact of Postoperative Complications on Long-Term Survival After Resection for Rectal Cancer. Dis Colon Rectum (2013) 56(1):20–8. doi: 10.1097/DCR.0b013e31826f2672

9. Derka W, de Leeuw RJ, Hordijk GJ, Elderly Patients With Head and Neck Cancer: The Influence of Comorbidity on Choice of Therapy, Complication Rate, and Survival. Curr Opin Otolaryngol Head Neck Surg (2005) 13(2):92–6. doi: 10.1097/01.moo.0000156169.63204.39

10. Saeki H, Tsutsumi S, Tajiri H, Yukaya T, Tsutsumi R, Nishimura S, et al. Prognostic Significance of Postoperative Complications After Curative Resection for Patients With Esophageal Squamous Cell Carcinoma. Ann Surg (2017) 265(3):527–33. doi: 10.1097/sla.0000000000001692

11. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor Survival Rate in Patients With Postoperative Intra-Abdominal Infectious Complications Following Curative Gastrectomy for Gastric Cancer. Ann Surg Oncol (2013) 20(5):1575–83. doi: 10.1245/s10434-012-2720-9

12. Wang S, Xu L, Wang Q, Li J, Bai B, Li Z, et al. Postoperative Complications and Prognosis After Radical Gastrectomy for Gastric Cancer: A Systematic Review and Meta-Analysis of Observational Studies. World J Surg Oncol (2019) 17(1):52. doi: 10.1186/s12957-019-1593-9

13. Jung MK, Park YK, Seon JW, Kim KY, Cheong O, Ryu SY. Definition and Classification of Complications of Gastrectomy for Gastric Cancer Based on the Accordion Severity Grading System. World J Surg (2012) 36(10):2400–11. doi: 10.1007/s00268-012-1693-y

14. Yang K, Bang HJ, Almadani ME, Dy-Abalajon DM, Kim YN, Roh KH, et al. Laparoscopic Proximal Gastrectomy With Double-Tract Reconstruction by Intracorporeal Anastomosis With Linear Staplers. J Am Coll Surg (2016) 222 (5):e39–45. doi: 10.1016/j.jamcollsurg.2016.01.002

15. Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz A, Greene F. AJCC cancer staging manual. New York: Springer (2010).

16. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nazihomo A, et al. Adjuvant Chemotherapy for Gastric Cancer With S-1, an Oral Fluoropyrimidine. N Engl J Med (2007) 357(18):1810–20. doi: 10.1056/NEJMoa072252

17. Noh SH, Park SR, Yang HK, Chung HC, Chung JJ, Kim SW, et al. Adjuvant Capecitabine Plus Oxaliplatin for Gastric Cancer After D2 Gastrectomy (CLASSIC): 5-Year Follow-Up of an Open-Label, Randomised Phase 3 Trial. Lancet Oncol (2014) 15(12):1389–96. doi: 10.1016/s1470-2045(14)70473-5

18. Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, et al. Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients With Stage 2 and 3 Gastric Cancer. Ann Surg Oncol (2015) 22(1):224–31. doi: 10.1186/s12957-014-3494-2

19. Li SS, Udelsoan BV, Parkih A, Klemptner SJ, Clark JW, Roeland EJ, et al. Impact of Postoperative Complications and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. J Am Coll Surg (2020) 230(6):912–24. doi: 10.1016/j.jamcollsurg.2019.12.038

20. Jin LX, Sanford DE, Squires MH, Moses LE, Yan Y, Poultisides GA, et al. Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Ann Surg Oncol (2016) 23 (8):2398–408. doi: 10.1245/s10434-016-1512-7

21. Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, et al. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients With Complications After Gastrectomy. Ann Surg Oncol (2018) 25(9):2720–30. doi: 10.1007/s10434-018-6638-8

22. An JY, Kim KM, Kim YM, Cheong JH, Hyung WJ, Noh SH. Surgical Complications in Gastric Cancer Patients Preoperatively Treated With Chemotherapy: Their Risk Factors and Clinical Relevance. Ann Surg Oncol (2012) 19(8):2452–8. doi: 10.1007/s10434-012-2267-9

23. Kwon IG, Cho I, Choi YJ, Hyung WJ, Kim CR, Noh SH. Risk Factors for Complications During Surgical Treatment of Remnant Gastric Cancer. Gastric Cancer (2015) 18(2):390–6. doi: 10.1007/s10120-014-0369-8

24. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-Related Inflammation. Nature (2008) 454(7203):436–44. doi: 10.1038/nature07205

25. McMillan DC. Systemic Inflammation, Nutritional Status and Survival in Patients With Cancer. Curr Opin Clin Nutr Metab Care (2009) 12(3):223–6. doi: 10.1097/mco.0b013e3282a7902

26. Sierzega M, Kolodziejczyk P, Kulig J. Impact of Anastomotic Leakage on Long-Term Survival After Total Gastrectomy for Carcinoma of the Stomach. BJIS (British J Surgery) (2010) 97(7):1035–42. doi: 10.1002/bjs.7038

Conflict of Interest: WH reports receiving research grants from the Medtronic and GC Pharma, is the chief executive officer of Hutom, and holds its stock. He provided consultancy services to Ethicon and Verb Surgical outside of the submitted work.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Song, Lee, Choi, Cho, Kwon, Kim, Son, Kim, Jung and Hyung. This is an open-access article published under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.